According to updated results from TROPiCS-03, sacituzumab govetican, a Trop-2–directed antibody-drug conjugate, in the second-line setting for extensive stage small cell lung cancer (ES-SCLC) showed promising antitumor activity with manageable safety. 

These results were first presented by Afshin Dowlati, MD, Case Cancer Center at Case Western Reserve University, Cleveland, Ohio, at the 2024 World Conference on Lung Cancer.

The open-label, multicohort, phase 2 TROPiCS-03 trial enrolled 43 patients with ES-SCLC who had progressed following ≤1 prior line of platinum-based chemotherapy an anti-PD(L)1 therapy. Patients received 10 mg/kg of sacituzumab govetican on day 1 and day 8 of a 21-day cycle. The primary end point of this trial was objective response rate (ORR), with secondary end points including clinical benefit rate (CBR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Preliminary results from TROPiCS-03 trial found that sacituzumab govetican showed promising antitumor activity and manageable safety within the ES-SCLC cohort.

The median follow-up for this analysis was 12.3 months. There were 7 patients who were continuing on treatment. The ORR was 41.9% and the CBR was 48.8%. The median DOR was 4.7 months, the median PFS was 4.40 months, and the median OS was 13.60 months. Among platinum-resistant patients, the ORR was 35.0% and among platinum-sensitive patients, it was 47.8%. There were 60.5% of patients who experienced a grade ≥3 treatment-emergent, treatment-related adverse events. No treatment-emergent, treatment-related adverse events led to discontinuation of study treatment. One patient died due to a treatment-emergent, treatment-related adverse event (neutropenic sepsis).

According to study authors, sacituzumab govetican as a second-line treatment for ES-SCLC “demonstrated promising anti-tumor activity in the fully enrolled ES-SCLC cohort.” They added that this activity “was seen in patients with both platinum-resistant and -sensitive disease.”

Source:

Dowlati A, Chiang AC, Cervantes A, et al. Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer. Presented at the World Conference on Lung Cancer; September 7-10, 2024. San Diego, CA. Abstract OA04.04.